Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

ClinicalTrials.gov ID: NCT01571414

Public ClinicalTrials.gov record NCT01571414. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I, Three-Arm Safety, Tolerability, and Pharmacokinetic Interaction Study of PA-824, an Investigational Nitroimidazole for the Treatment of Tuberculosis, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

Study identification

NCT ID
NCT01571414
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
52 participants

Conditions and interventions

Conditions

Interventions

  • PA-824 Drug
  • Efavirenz (EFV) Drug
  • Lopinavir/Ritonavir (LPV/r) Drug
  • Rifampin (RIF) Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2012
Primary completion
Apr 30, 2013
Completion
Apr 30, 2013
Last update posted
Nov 4, 2021

2012 – 2013

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
Ucsf Hiv/Aids Crs San Francisco California 94110
Johns Hopkins University CRS Baltimore Maryland 21205
Ohio State University CRS Columbus Ohio 43210
Vanderbilt Therapeutics (VT) CRS Nashville Tennessee 37204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01571414, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 4, 2021 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01571414 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →